Scholar Rock to Participate in Upcoming Investor Conferences
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focusing on treatments for spinal muscular atrophy, cardiometabolic disorders, and diseases involving protein growth factors, has announced its participation in three upcoming investor conferences. The company will present at the Truist Securities BioPharma Symposium on November 7, the Jefferies London Healthcare Conference on November 20, and the Piper Sandler Healthcare Conference on December 4. Live webcasts will be available on Scholar Rock's website, with replays accessible for approximately 90 days.
Scholar Rock (NASDAQ: SRRK), un'azienda biofarmaceutica in fase avanzata che si concentra su trattamenti per atrofia muscolare spinale, disturbi cardiometabolici e malattie legate ai fattori di crescita proteici, ha annunciato la sua partecipazione a tre prossime conferenze per investitori. L'azienda presenterà al Truist Securities BioPharma Symposium il 7 novembre, alla Jefferies London Healthcare Conference il 20 novembre e alla Piper Sandler Healthcare Conference il 4 dicembre. Le dirette streaming saranno disponibili sul sito web di Scholar Rock, con le registrazioni accessibili per circa 90 giorni.
Scholar Rock (NASDAQ: SRRK), una compañía biofarmacéutica en etapa avanzada que se enfoca en tratamientos para atrofia muscular espinal, trastornos cardiometabólicos y enfermedades relacionadas con factores de crecimiento proteico, ha anunciado su participación en tres próximas conferencias para inversores. La compañía presentará en el Truist Securities BioPharma Symposium el 7 de noviembre, en la Jefferies London Healthcare Conference el 20 de noviembre y en la Piper Sandler Healthcare Conference el 4 de diciembre. Las transmisiones en vivo estarán disponibles en el sitio web de Scholar Rock, con repeticiones accesibles durante aproximadamente 90 días.
Scholar Rock (NASDAQ: SRRK)는 척수 근위축증, 심장 대사 장애 및 단백질 성장 인자 관련 질환 치료에 집중하는 후기 단계의 생물 제약 회사로, 다가오는 세 곳의 투자자 회의에 참여할 것이라고 발표했습니다. 이 회사는 11월 7일 Truist Securities BioPharma Symposium에서, 11월 20일 Jefferies London Healthcare Conference에서, 그리고 12월 4일 Piper Sandler Healthcare Conference에서 발표할 예정입니다. Scholar Rock의 웹사이트에서 실시간 웹캐스트를 제공하며, 약 90일 동안 다시 보기를 할 수 있습니다.
Scholar Rock (NASDAQ: SRRK), une entreprise biopharmaceutique en phase avancée axée sur les traitements de l'atrophie musculaire spinale, des troubles cardiométaboliques et des maladies liées aux facteurs de croissance des protéines, a annoncé sa participation à trois prochaines conférences pour investisseurs. L'entreprise présentera lors du Truist Securities BioPharma Symposium le 7 novembre, à la Jefferies London Healthcare Conference le 20 novembre, et à la Piper Sandler Healthcare Conference le 4 décembre. Des webcasts en direct seront disponibles sur le site web de Scholar Rock, avec des rediffusions accessibles pendant environ 90 jours.
Scholar Rock (NASDAQ: SRRK), ein biopharmazeutisches Unternehmen in der späten Phase, das sich auf Behandlungen für spinale Muskelatrophie, kardiometabolische Erkrankungen und Krankheiten mit Wachstumsfaktoren für Proteine konzentriert, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 7. November beim Truist Securities BioPharma Symposium, am 20. November bei der Jefferies London Healthcare Conference und am 4. Dezember bei der Piper Sandler Healthcare Conference präsentieren. Live-Übertragungen werden auf der Website von Scholar Rock verfügbar sein, mit Wiederholungen, die ungefähr 90 Tage lang zugänglich sind.
- None.
- None.
-
Truist Securities BioPharma Symposium: Scholar Rock is scheduled to participate in a panel presentation at 3:25 p.m. ET on Thursday, November 7 in
New York City . -
Jefferies London Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 4:30 p.m. GMT on Wednesday, November 20 in
London . -
Piper Sandler 36th Annual Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 1:30 p.m. ET on Wednesday, December 4 in
New York City .
A live webcast of the events may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. Archived replays of the webcasts will be available on the Company’s website for approximately 90 days.
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031493371/en/
Scholar Rock:
Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Media
Molly MacLeod
Scholar Rock
mmacleod@scholarrock.com
media@scholarrock.com
802-579-599
Source: Scholar Rock
FAQ
When is Scholar Rock (SRRK) presenting at the Truist Securities BioPharma Symposium?
What time is Scholar Rock's (SRRK) presentation at the Jefferies London Healthcare Conference?
Where can investors watch Scholar Rock's (SRRK) conference presentations?
Which investor conferences is Scholar Rock (SRRK) attending in late 2023?
